Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa reported Q1 financials with a net loss of $44.5 million and collaboration revenue of $4.2 million, while highlighting a strengthened balance sheet of $671.2 million that supports operations into 2029. Clinical updates included positive interim data for MRT-8102 showing an 85% reduction in CRP levels, with multiple Phase 2 studies planned for H2 2026.
Key figures
- Revenue
- $4.2 million
- Net loss
- $44.5 million
- Ga expenses
- $10.2 million
- Rd expenses
- $44.1 million
- Cash position
- $671.2 million
- Crp reduction
- 85%
- Offering proceeds january
- $345.0 million
- Disease control rate mrt2359
- 67%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.